Research map: Limiting Dexamethasone Exposure With Highly Emetogenic Chemotherapy Regimens: Is the Verdict In?

Back to the article

Papers in this map

  1. Chemotherapy-Induced Nausea and Vomiting · Paul Joseph Hesketh · 2008 · 838 citations · Cited by this paper
  2. Statistical and Methodological Considerations in the Evaluation of Ultra-Low-Dose Nivolumab · 2026 · Related
  3. Antiemetics: ASCO Guideline Update · Paul Joseph Hesketh · 2020 · 479 citations · Cited by this paper
  4. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research Program · 2026 · Related
  5. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting · Jørn Herrstedt · 2024 · 176 citations · Cited by this paper
  6. Innovate or Be Left Behind: A Path to Prospective External Control Arms for Accelerated Oncology Drug Development · 2026 · Related
  7. Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy · Yuka Ito · 2018 · 78 citations · Cited by this paper
  8. AAML1831: A Phase III Trial Comparing Standard Induction Therapy With CPX-351 in De Novo Pediatric AML: A Report From the Children's Oncology Group · 2026 · Related
  9. Prevention of acute and delayed chemotherapy‐induced nausea and vomiting in pediatric cancer patients: A clinical practice guideline · Priya Patel · 2022 · 57 citations · Cited by this paper
  10. Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up · 2026 · Related
  11. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence · Luigi Celio · 2019 · 40 citations · Cited by this paper
  12. Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor · 2026 · Related
  13. One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis · Yuki Okada · 2019 · 39 citations · Cited by this paper
  14. SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1–High, Locally Advanced, Unresectable or Metastatic Non–Small Cell Lung Cancer · 2026 · Related
  15. Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial · Ramavath Devendra Naik · 2020 · 33 citations · Cited by this paper
  16. Moderate Hypofractionation for Regional Node Irradiation Is Safe and Effective · 2026 · Related
  17. Palonosetron in combination with 1-day versus 3-day dexamethasone to prevent nausea and vomiting in patients receiving paclitaxel and carboplatin · Naoto Furukawa · 2015 · 25 citations · Cited by this paper
  18. Beyond Statistical Significance: Methodological Fragility and Censoring Bias in the 5-Year Update of CheckMate 743 · 2026 · Related
  19. Dexamethasone-sparing on days 2–4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial) · Hiroko Minatogawa · 2023 · 19 citations · Cited by this paper
  20. Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update · 2026 · Related
  21. Palonosetron in combination with 1‐day versus 3‐day dexamethasone for prevention of nausea and vomiting following paclitaxel and carboplatin in patients with gynecologic cancers: A randomized, multicenter, phase‐II trial · Motoki Matsuura · 2015 · 16 citations · Cited by this paper
  22. Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial · Yanchun Meng · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)